Zupanec, S., Beauchemin, M., & Rau, R. E. (2025). Navigating B-ALL in the Era of Blinatumomab. American Society of Clinical Oncology Educational Book, 45(3). https://doi.org/10.1200/edbk-25-472778

Xu, J., Zhou, T., McKee, K., Zhang, B., Liu, C., Nazzari, A. F., Pegu, A., Shen, C., Becker, J. E., Bender, M. F., Chan, P., Changela, A., Chaudhary, R., Chen, X., Einav, T., Kwon, Y. D., Lin, B. C., Louder, M. K., Merriam, J. S., … Kwong, P. D. (2024). Ultrapotent Broadly Neutralizing Human‐llama Bispecific Antibodies against HIV‐1. Advanced Science, 11(26). Portico. https://doi.org/10.1002/advs.202309268

Bumma, N., Richter, J., Jagannath, S., Lee, H. C., Hoffman, J. E., Suvannasankha, A., Zonder, J. A., Shah, M. R., Lentzsch, S., Baz, R., Maly, J. J., Namburi, S., Pianko, M. J., Ye, J. C., Wu, K. L., Silbermann, R., Min, C.-K., Vekemans, M.-C., Munder, M., … Dhodapkar, M. V. (2024). Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology, 42(22), 2702–2712. https://doi.org/10.1200/jco.24.01008

Wang, K., Du, R., Myall, N. J., Lewis, W. E., Uy, N., Hong, L., Skoulidis, F., Byers, L. A., Tsao, A., Cascone, T., Pozadzides, J., Tu, J., Negrao, M. V., Gibbons, D. L., Park, K., Rinsurongkawong, W., Lee, J. J., Gandara, D., Behl, D., … Le, X. (2024). Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. Journal of Thoracic Oncology, 19(3), 500–506. https://doi.org/10.1016/j.jtho.2023.11.020

Park, K., Sabari, J. K., Haura, E. B., Shu, C. A., Spira, A., Salgia, R., Reckamp, K. L., Sanborn, R. E., Govindan, R., Bauml, J. M., Curtin, J. C., Xie, J., Roshak, A., Lorenzini, P., Millington, D., Thayu, M., Knoblauch, R. E., & Cho, B. C. (2023). Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. Lung Cancer, 178, 166–171. https://doi.org/10.1016/j.lungcan.2023.02.008

Burke, A., Borot, F., Du, X., Churchill, M., Ding, J., Grass, A. M., DeSouza, P., Ali, A. M., & Mukherjee, S. (2022). A novel therapeutic bispecific format based on synthetic orthogonal heterodimers enables T cell activity against Acute myeloid leukemia. Oncogene, 42(1), 26–34. https://doi.org/10.1038/s41388-022-02532-2

Tavaré, R., Danton, M., Giurleo, J. T., Makonnen, S., Hickey, C., Arnold, T. C., Kelly, M. P., Fredriksson, F., Bruestle, K., Hermann, A., Ullman, E., Edelmann, K. H., Potocky, T., Dudgeon, D., Bhatt, N. B., Doubrovin, M., Barry, T., Kyratsous, C. A., Gurer, C., … Kirshner, J. R. (2022). Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054. Cancer Immunology Research, 10(10), 1190–1209. https://doi.org/10.1158/2326-6066.cir-21-0405

Park, K., Haura, E. B., Leighl, N. B., Mitchell, P., Shu, C. A., Girard, N., Viteri, S., Han, J.-Y., Kim, S.-W., Lee, C. K., Sabari, J. K., Spira, A. I., Yang, T.-Y., Kim, D.-W., Lee, K. H., Sanborn, R. E., Trigo, J., Goto, K., Lee, J.-S., … Cho, B. C. (2021). Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. Journal of Clinical Oncology, 39(30), 3391–3402. https://doi.org/10.1200/jco.21.00662